A novel VEGFR3 mutation causes Milroy disease

American Journal of Medical Genetics, Part A

Volumn 143, Issue 11, 2007, Pages 1212-1217

  Butler, Matthew G ^a,c   Dagenais, Susan L ^a   Rockson, Stanley G ^b   Glover, Thomas W ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Lymphedema; Milroy disease; VEGFR3

Indexed keywords

PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 3;

ALLELE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL ARTICLE; CLINICAL FEATURE; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MALE; MILROY DISEASE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; BASE SEQUENCE; CONSERVED SEQUENCE; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; HUMANS; LYMPHEDEMA; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PEDIGREE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 34249902300     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31703     Document Type: Article

References (20)

1. Brice G, Child AH, Evans A, Bell R, Mansour S, Burnand K, Sarfarazi M, Jeffery S, Mortimer P. 2005. Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet 42:98-102.
2. Ciulla TA, Sklar RM, Hauser SL. 1988. A simple method for DNA purification from peripheral blood. Anal Biochem 174:485-488.
3. Daniel-Spiegel E, Ghalamkarpour A, Spiegel R, Weiner E, Vikkula M, Shalev E, Shalev SA. 2005. Hydrops fetalis: An unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn 25:1015-1018.
4. Evans AL, Brice G, Sotirova V, Mortimer P, Beninson J, Burnand K, Rosbotham J, Child A, Sarfarazi M. 1999. Mapping of primary congenital lymphedema to the 5q35.3 region. Am J Hum Genet 64:547-555.
5. Evans AL, Bell R, Brice G, Comeglio P, Lipede C, Jeffrey S, Mortimer P, Safarazi M, Child AH. 2003. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphodema. JMG 40:697-703.
6. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH, Glover TW. 2000. Mutations in FOXC2 (MFH-1), a
7. forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am J Hum Genet 67:1382-1388.
8. Ferrell RE, Levinson KL, Esman JH, Kimak KA, Lawrence EC, Barmada MM, Finegold DN. 1998. Hereditary lymphedema: Evidence for linkage and genetic heterogeneity. Hum Mol Genet 7:2073-2078.
9. Ghalamkarpour A, Morlot S, Raas-Rothschild A, Utkus A, Mulliken JB, Boon LM, Vikkula M. 2006. Hereditary lymphedema type I associated with VEGFR3 mutation: The first de novo case and atypical presentations. Clin Genet 70:330-335.
10. Holberg JH, Erickson RP, Bernas MJ, Witte MH, Fultz KE, Andrade M, Witte CL. 2001. Segregation analysis and a genome wide linkage search confirm genetic heterogeneity and suggest oliogogenic inheritance in some Milroy congenital primary lymphedema families. Am J Med Genet 98:303-312.
11. Iljin K, Karkkainen MJ, Lawrence EC, Kimak MA, Uutela M, Taipale J, Pajusola K, Alhonen L, Halmekyto M, Finegold DN, Ferrell RE, Alitalo K. 2001. VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J 15:1028-1036.
12. Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. 2000. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 67:295-301.
13. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K. 1995. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. PNAS 92:3566-3570.
14. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. 2000. Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema. Nat Genet 25:153-159.
15. Mizuno S, Yamada Y, Yamada K, Nomura N, Wakamatsu N. 2005. Clinical variability in a Japanese hereditary lymphedema type 1 family with an FLT4 mutation. Congenit Anom 4: 59-61.
16. Mortimer PS. 1995. Managing lymphedema. Clin Dermatol 13: 499-505.
17. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K. 2000. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 14:2087-2096.
18. Spiegel R, Ghalamkarpour A, Daniel-Spiegel E, Vikkula M, Shalev SA. 2006. Wide clinical spectrum in a family with hereditary lymphedema type I due to a novel missense mutation in VEG FR3. J Hum Genet 51:846-850.
19. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
20. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG, Stacker SA, Alitalo K. 2001. Signaling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20:1223-1231.